Dentsply Sirona Inc (XRAY)

Nov 6, 2026

Dentsply Sirona (NASDAQ: XRAY) shares dropped 7% after the company reported a GAAP diluted loss per share for Q3 2026 and lowered its full-year financial outlook, missing Wall Street estimates. The company's net sales were $836 million, with a GAAP diluted loss of $0.01 per share. Dentsply Sirona now forecasts full-year 2026 net sales of approximately $3.5 billion and adjusted earnings per share between $1.20 and $1.30.

Nov 6, 2026

Dentsply Sirona, a major dental equipment manufacturer, faces market challenges and margin pressure, leading to lowered guidance and uncertain recovery timing. The company is adapting by investing in its Cerec chairside workflow system and expanding partnerships to open up its historically closed system and broaden its end markets. This strategic shift aims to help Dentsply compete in an increasingly fragmented market.

Nov 5, 2026

DENTSPLY SIRONA (NASDAQ:XRAY) announced its quarterly earnings, reporting $0.29 EPS, missing analysts' consensus of $0.31, and revenue of $836 million, below estimates of $861.68 million. The company also cut its FY 2026 guidance for adjusted EPS to $1.20–$1.30 and sales to approximately $3.5 billion. Following the announcement, XRAY stock traded down 5.3%, hitting $10.09.

Nov 5, 2026

Dentsply Sirona reported Q3 2026 revenue of $836 million, a 7.6% decline, and lowered its full-year net sales outlook to $3.5 billion with adjusted EPS between $1.20 and $1.30. The company is advancing its Return to Growth Action Plan by investing in clinical education, sales force expansion, and product innovation, showing early successes in Wellspect Healthcare and U.S. value implants and endodontic products. Management emphasized improved financial visibility, cost management, and debt reduction as key priorities moving forward.

Nov 5, 2026

Dentsply Sirona (NASDAQ:XRAY) reported Q3 2026 revenue of $836 million, missing analysts' consensus estimates by 2.7% and representing a 7.5% year-on-year decline. The company also missed adjusted EPS estimates and lowered its full-year revenue and adjusted EPS guidance, leading to a 14.4% drop in its stock price. Despite these setbacks, the CEO noted progress in their "Return-to-Growth Action Plan."

Nov 5, 2026

Dentsply International (XRAY) reported Q3 earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.30, and revenues of $836 million, falling short of the $856 million estimate. The dental products manufacturer has surpassed EPS estimates only once in the last four quarters and has a Zacks Rank #4 (Sell), indicating expected underperformance in the near future. The stock has lost 6.8% year-to-date, lagging the S&P 500's 12.3% gain.

Oct 28, 2026

Dentsply Sirona is a major global manufacturer of dental equipment and supplies. An Argus report from January 21, 2026, lowered the target price for XRAY to $11.00, with the current price at $9.44. The report provides a quantitative analysis and earnings estimate for the healthcare sector company.